SCHEMBL940108

SCHEMBL940108

CN(Cc1nc2cccc(C(=O)N3CCC4(CC3)CCN(c3ccncc3)CC4)c2[nH]1)C(=O)c1ccc(Cl)s1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 10/20 0.43
CYP3A4 P08684 9/20 0.43
CYP2D6 P10635 9/20 0.43
CYP1A2 P05177 6/20 0.43
TSHR P16473 6/20 0.43
HIF1A Q16665 5/20 0.43
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 6/20 0.41
CYP2C19 P33261 6/20 0.41
BDKRB1 P46663 1/20 0.39
USP2 O75604 2/20 0.39
MAPK1 P28482 2/20 0.39
HPGD P15428 1/20 0.39
MAPT P10636 1/20 0.38
ITGB3 P05106 2/20 0.37
ITGA2B P08514 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL939340 0.88 CYP2C9 (0.45) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL939674 0.87 CYP3A4 (0.42) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL11947923 0.87 CYP3A4 (0.40) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL938493 0.84 CYP2C19 (0.42) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL938797 0.83 CYP2D6 (0.48) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL938301 0.83 ITGB3 (0.40) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL939921 0.80 CYP2C9 (0.40) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL938398 0.79 CYP3A4 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL939306 0.79 CYP3A4 (0.40) CYP2C9CYP3A4CYP2D6CYP1A2TSHR
SCHEMBL940776 0.78 CYP2D6 (0.47) CYP2C9CYP3A4CYP2D6CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP claimed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US claimed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US claimed
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP disclosed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US disclosed
EP-2440542-A1 SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES Grünenthal GmbH (DE) 2012-04-18 EP disclosed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US disclosed
WO-2010142402-A1 SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES Grünenthal GmbH (DE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles BDKRB1, BDKRB2, BRD1 CYP2C9 362/4885CYP3A4 253/4885CYP2D6 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.